Invasive Ductal Carcinoma is one of the most common type of Breast Cancer. In this, the cancer began in the milk ducts and spreads to the nearby breast tissues. Invasive Ductal Carcinoma diagnosis includes physical examination of the breasts and imaging tests such as mammography, ultrasound, Breasts MRI or Biopsy (HER-2 levels measurement). Treatment for IDC includes local treatments such as surgery and radiation therapy or systemic treatments such as chemotherapy, hormone therapy and targeted therapy.

Treatment type also depends upon the size of the tumor, stage of cancer and grade of cancer cells. Many treatments and screening methods are in the market these days which helps in early detection and has increased the survival rates in patients. Invasive ductal Carcinoma mostly occurs with women of older age. Many patient support programs and campaigns are organized nowadays, in several countries raising awareness about breast cancer and thus fueling the market.       

According to WHO, breast cancer accounted for 11.9 percent of the total cancer cases reported and resulted in 5, 22,000 deaths worldwide IN 2012. According to the American Cancer Society, more than 180,000 women in US are found to have invasive breast cancer every year and most of them are detected with invasive ductal carcinoma. Thus, the demand for treatment is progressive.

Invasive Ductal Carcinoma market is rapidly evolving market because of increase in the number of patients increase in aging population and more available treatment options. Other factors like support from the government and initiatives of nonprofit organizations increase the awareness and more available screening techniques can diagnose more suspects and thus will grow the treatment market.

The expense in the treatment limits its affordability and availability to all the sections of the society and curbs the market growth. Some other factors like drug resistance, side-effects, lack of awareness also limits the market growth. Less painful, more effective and affordable treatment is the need required for the growth of Invasive Ductal Carcinoma treatment market. Improvisation in the available drugs and the delivery systems for the treatment is the key challenge for the biopharmaceutical industries.

A geographic condition regarding the castration-resistant prostate cancer treatment market, it has been segmented into five key regions: North America, Latin America, Europe, Asia-Pacific and the Middle East & Africa.  Current trend shows that North America dominates the global market for Invasive Ductal Carcinoma Treatment followed by Europe because of large number of patient pool, availability of high throughput technology and reimbursement scenario in these countries.

Asia- Pacific also shows future increase in the market because of increasing patients with breast cancer, more government initiatives, increasing R&D investments, growing economies and other factors.

Some of the global key players in the Invasive Ductal Carcinoma Treatment Market includes Eli Lilly and Company, Merck & Co., Inc., Pfizer Inc, Celgene Corporation, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Biocon, Novartis AG, AbbVie Inc., AstraZeneca plc. and others.

• Invasive Ductal Carcinoma Treatment Market Segments.
• Invasive Ductal Carcinoma Treatment Market Dynamics.
• Historical Actual Market Size, 2015 – 2016.
• Invasive Ductal Carcinoma Treatment Market Size & Forecast 2017 to 2025.
• Invasive Ductal Carcinoma Treatment Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Invasive Ductal Carcinoma Treatment Market Drivers and Restraints

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size Recent industry trends
• Key Competition landscape
• Strategies of key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance